Biocon Receives USFDA Approval for Liraglutide Weight Management Drug

Biocon has received approval from the U.S. Food and Drug Administration for its Liraglutide Injection, a drug-device combination used to manage chronic weight issues alongside diet and exercise. This approval marks a significant milestone for Biocon, highlighting its capabilities in developing complex therapies. GLP-1 receptor agonists like Liraglutide are rapidly growing globally due to rising obesity rates and strong clinical outcomes, with the U.S. market presenting substantial opportunities.